UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.

09/03/2024 09/03/2024

MindMed announces positive 12-week data from phase 2B study of MM120 for GAD

FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD)."

09/12/2023 09/12/2023

Greater subjective effects of a low dose of LSD in participants with depressed mood

These findings suggest that an acute low dose of LSD (26 µg) elicits more pronounced positive mood and stimulant-like effects, as well as stronger altered states of consciousness in individuals with depressive symptoms, compared to non-depressed individuals.

03/06/2023 03/06/2023

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants

The results indicate that any differences in the pharmacological profiles of mescaline, LSD, and psilocybin do not translate into relevant differences in the subjective experience.

13/05/2023 13/05/2023

Dose-response relationships of LSD-induced subjective experiences in humans

Most scales revealed a sigmoid-like increase of effects, with a plateauing at around 100 μg.

26/04/2023 26/04/2023

Classical and non-classical psychedelic drugs induce common network changes in human cortex

08/04/2023 08/04/2023

Acute mood-elevating properties of microdosed LSD in healthy volunteers: a home-administered randomised controlled trial

Daily questionnaires showed credible evidence (>99% posterior probability) of improved ratings of creativity, connectedness, energy, happiness, irritability, and wellness